Logo image
Back
Characterization of murine Caraparu Bunyavirus liver infection and immunomodulator-mediated antiviral protection
Journal article   Peer reviewed

Characterization of murine Caraparu Bunyavirus liver infection and immunomodulator-mediated antiviral protection

M.A. Brinton, E.I. Gavin, W.-K. Lo, A.J. Pinto and P.S. Morahan
Antiviral research, v 20(2)
1993
DOI: https://doi.org/10.1016/0166-3542(93)90005-4
PMID: 8460932
Featured in Collection :   UN Sustainable Development Goals @ Drexel

Abstract

Immunomodulator Murine Caraparu Bunyavirus Ribavirin
A rapid, peripheral disease model utilizing the Bunyavirus, Caraparu, was established in mice for the evaluation of antiviral therapy with immunomodulators. 4–6-week-old B6C3F1 female mice, inoculated intraperitoneally with virus, developed coagulative liver necrosis and died between 4–6 days after infection. This Caraparu disease model was relatively resistant to treatment with immunomodulators, such as ABMP, Ampligen, α-interferon (IFN-α) or β-interferon (IFN-β). However, a significant increase in median survival time (MST) was consistently observed upon treatment with γ-interferon (IFN-γ). The nucleoside analog - ribavirin - was highly effective against Caraparu virus in repeated treatment schedules begun on either day −1, day 0, or day +1 of infection. Ribavirin gave little protection when initiation of treatment was delayed until day +2. However, combined treatment with IFN-γ, starting on day 0 and ribavirin starting on day +2, significantly reduced mortality.

Metrics

6 Record Views
4 citations in Web of Science
7 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Pharmacology & Pharmacy
Virology
Logo image